Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First in Patient, Dose Escalation, Open Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Infusion of BAY 3389934 to Patients With Sepsis Induced Coagulopathy

NCT06854640 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT06854640
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06854640 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First in Patient, Dose Escalation, Open Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Infusion of BAY 3389934 to Patients With Sepsis Induced Coagulopathy
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Recruiting
Start date
March 12, 2025
Completion date
January 17, 2027
Enrollment
36 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

coagulopathy, sepsis